Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.

Pavord ID, Buhl R, Kraft M, Prazma CM, Price RG, Howarth PH, Yancey SW

Open source

DOI
10.1183/23120541.00560-2021
Published
2022 Apr
Container
ERJ open research
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1183/23120541.00560-2021,
  title = {Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.},
  author = {Pavord ID and Buhl R and Kraft M and Prazma CM and Price RG and Howarth PH and Yancey SW},
  year = {2022},
  journal = {ERJ open research},
  doi = {10.1183/23120541.00560-2021},
  url = {https://doi.org/10.1183/23120541.00560-2021}
}

RIS

TY  - JOUR
TI  - Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.
AU  - Pavord ID
AU  - Buhl R
AU  - Kraft M
AU  - Prazma CM
AU  - Price RG
AU  - Howarth PH
AU  - Yancey SW
PY  - 2022
JO  - ERJ open research
DO  - 10.1183/23120541.00560-2021
UR  - https://doi.org/10.1183/23120541.00560-2021
ER  - 

APA

ID, P., R, B., M, K., CM, P., RG, P., PH, H., & SW, Y. (2022). Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.. ERJ open research. https://doi.org/10.1183/23120541.00560-2021

Source records